Literature DB >> 20353397

Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Rosamund Chapman1, Gerald Chege, Enid Shephard, Helen Stutz, Anna-Lise Williamson.   

Abstract

HIV-1 has resulted in a devastating AIDS pandemic. An effective HIV/AIDS vaccine that can be used to either, prevent HIV infection, control infection or prevent progression of the disease to AIDS is needed. In this review we discuss the use of Mycobacterium bovis BCG, the tuberculosis vaccine, as a vaccine vector for an HIV vaccine. Numerous features make BCG an attractive vehicle to deliver HIV antigens. It has a good safety profile, elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable, a necessary consideration for developing countries. In this review we discuss the numerous factors that influence generation of a genetically stable recombinant BCG vaccine for HIV.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20353397      PMCID： PMC3188323          DOI： 10.2174/157016210791208686

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN： 1570-162X            Impact factor:   1.581


  178 in total

1.  Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys.

Authors:  Paula M Acierno; Jörn E Schmitz; Darci A Gorgone; Yue Sun; Sampa Santra; Michael S Seaman; Michael H Newberg; John R Mascola; Gary J Nabel; Dennis Panicali; Norman L Letvin
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galić
Journal:  Vaccine       Date:  2005-10-11       Impact factor: 3.641

3.  Green fluorescent protein as a marker for gene expression and cell biology of mycobacterial interactions with macrophages.

Authors:  S Dhandayuthapani; L E Via; C A Thomas; P M Horowitz; D Deretic; V Deretic
Journal:  Mol Microbiol       Date:  1995-09       Impact factor: 3.501

4.  HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions.

Authors:  T Hiroi; H Goto; K Someya; M Yanagita; M Honda; N Yamanaka; H Kiyono
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

5.  Route of BCG administration in possums affects protection against bovine tuberculosis.

Authors:  F E Aldwell; D L Keen; V C Stent; A Thomson; G F Yates; G W de Lisle; B M Buddle
Journal:  N Z Vet J       Date:  1995-12       Impact factor: 1.628

6.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop.

Authors:  M Kameoka; Y Nishino; K Matsuo; N Ohara; T Kimura; A Yamazaki; T Yamada; K Ikuta
Journal:  Vaccine       Date:  1994-02       Impact factor: 3.641

8.  Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.

Authors:  Duanthanorm Promkhatkaew; Nadthanan Pinyosukhee; Wilai Thongdeejaroen; Reungpung Sutthent; Pathom Sawanpanyalert; Paijit Warachit
Journal:  Southeast Asian J Trop Med Public Health       Date:  2009-01       Impact factor: 0.267

9.  Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection.

Authors:  Julia Vipond; Martin L Cross; Matthew R Lambeth; Simon Clark; Frank E Aldwell; Ann Williams
Journal:  Microbes Infect       Date:  2008-09-23       Impact factor: 2.700

10.  Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis.

Authors:  S M Behar; C C Dascher; M J Grusby; C R Wang; M B Brenner
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307
View more
  19 in total

1.  Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection.

Authors:  Christof Geldmacher; Richard A Koup
Journal:  Trends Immunol       Date:  2012-03-05       Impact factor: 16.687

2.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

3.  Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cells.

Authors:  Dhaniah Mohamad; Rapeah Suppian; Norazmi Mohd Nor
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion.

Authors:  Natalie Taylor; Faith Bahunde; Afton Thompson; Jae-Sung Yu; William R Jacobs; Norm L Letvin; Barton F Haynes; Sunhee Lee
Journal:  Clin Vaccine Immunol       Date:  2012-07-11

5.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

6.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.

Authors:  Jaimie D Sixsmith; Michael W Panas; Sunhee Lee; Geoffrey O Gillard; KeriAnn White; Michelle A Lifton; Harikrishnan Balachandran; Linh Mach; John P Miller; Christy Lavine; C Todd DeMarco; Georgia D Tomaras; Connie Gee; Steven A Porcelli; Michelle H Larsen; Richard Frothingham; Joern E Schmitz; William R Jacobs; Barton F Haynes; Norman L Letvin; Birgit Korioth-Schmitz
Journal:  Clin Vaccine Immunol       Date:  2014-07-30

Review 7.  Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.

Authors:  Muhammed O Afolabi; Jane U Adetifa; Egeruan B Imoukhuede; Nicola K Viebig; Beate Kampmann; Kalifa Bojang
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

8.  Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.

Authors:  Rosamund Chapman; Enid Shephard; Helen Stutz; Nicola Douglass; Vasan Sambandamurthy; Irene Garcia; Bernhard Ryffel; William Jacobs; Anna-Lise Williamson
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 9.  HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies.

Authors:  Nyasha Chin'ombe; Vurayai Ruhanya
Journal:  Pan Afr Med J       Date:  2015-04-20

10.  A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.

Authors:  Muhammed O Afolabi; Jorjoh Ndure; Abdoulie Drammeh; Fatoumatta Darboe; Shams-Rony Mehedi; Sarah L Rowland-Jones; Nicola Borthwick; Antony Black; Gwen Ambler; Grace C John-Stewart; Marie Reilly; Tomáš Hanke; Katie L Flanagan
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.